Non-Surgical Periodontal Therapy Reduces Coronary Heart Disease Risk Markers: A Randomized Controlled Trial Bokhari SAH, Khan AA, Butt AK, Azhar M, Hanif.

Slides:



Advertisements
Similar presentations
ASCOT ASCOT STUDY. ASCOT INTRODUCTION AND AIMS EXISTING KNOWLEDGE BACKGROUND OF ASCOT STUDY DESIGN (TWO ARMS (BPLA,LLA) METHODOLOGY TREATMENT REGIMES.
Advertisements

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: A pilot double- blind, randomized controlled trial Critical Care Medicine.
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
Journal Club Alcohol and Health: Current Evidence January–February 2007.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
USE OF TOPICAL DESSICANT AGENT (HYBENX®) AS AN ADJUNCT TO ULTRASONIC DEBRIDEMENT IN THE INITIAL TREATMENT OF CHRONIC PERIODONTITIS: A CLINICAL AND MICROBIOLOGICAL.
Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
EUGIS European Union Garlic Inflammation Study in Humans.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Relationship between total cholesterol and 90-day mortality after acute myocardial infarction in patients not on statins Rishi Parmar 2 nd year Medicine.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Federal Study of Adherence to Medications (FAME) Trial Presented at The American Heart Association Annual Scientific Session 2006 Presented by Dr. Allen.
Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results SJ Nicholls, GL Bakris, JJP Kastelein, V Menon,
European Union Garlic Inflammation Study (EUGIS) in Humans Martijn van Doorn Sonia Espirito Santo TNO-PH Leiden The Netherlands CHDR Leiden The Netherlands.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Polypill x Aspirin Project Groups 3 and 4
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
Anne L. Taylor, M. D. , Susan Ziesche, R. N. , Clyde Yancy, M. D
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
Clinical Trial Results. org RAAVE Luis M. Moura, MD; Sandra F. Ramos, MSc; José L. Zamorano, MD, PhD; Isabel M. Barros, MD; Luis F. Azevedo, MD; Francisco.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Herpes Viruses, Cytokines & Hemostasis in Vital Exhaustion A psychobiological pathway to coronary artery disease?
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised,placebo-controlled.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
AZITHROMYCIN AS AN ADJUNCTIVE TREATMENT OF GENERALIZED SEVERE CHRONIC PERIODONTITIS: CLINICAL, MICROBIOLOGIC AND BIOCHEMICAL PARAMETERS Buket Han, Gulnur.
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Efficacy of Colchicine When Added to Traditional Anti- Inflammatory Therapy in the Treatment of Pericarditis Efficacy of Colchicine When Added to Traditional.
Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.
INCREASED RISK OF MYOCARDIAL INFARCTION AND STROKE FOLLOWING EXACERBATION OF COPD Gavin C. Donaldson, PhD ; John R. Hurst, PhD ; Christopher J. Smith,
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Angela Aziz Donnelly April 5, 2016
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Title Investigators and sites. Clinical Trial Proposal Presentation Template for open forum at the 2017 ASM.
The ALERT Trial.
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Effect of Periodontal Therapy on GCF and Serum Levels of High-Sensitive C- reactive protein in Chronic Periodontitis Patients Alaa M Attia: Associate.
The HEMO Study Hemodialysis (HEMO) Study Reference
Elevated Circulating Levels of Inflammatory Markers in
Dr. Alaa Moustafa Attia * Dr Mohamed Fouad Idress **
The Anglo Scandinavian Cardiac Outcomes Trial
AIM HIGH Niacin plus Statin to prevent vascular events
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
Oxford Niacin Trial.
RAAS Blockade: Focus on ACEI
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Section 5: Intervention and drug therapy
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
LRC-CPPT and MRFIT Content Points:
The following slides are from a Cardiology Scientific Update in which Dr. Gordon Moe reported and discussed an original presentation by Drs. Bjorn Dahlof,
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Presentation transcript:

Non-Surgical Periodontal Therapy Reduces Coronary Heart Disease Risk Markers: A Randomized Controlled Trial Bokhari SAH, Khan AA, Butt AK, Azhar M, Hanif M, Izhar M, Tatakis DN Journal of Clinical Periodontology 2012

 Periodontal Disease is a chronic inflammatory and infectious disease  Systematic Reviews and Meta- analysis have provided evidence for an association of Periodontal disease and CHD and PD has been found to be associated with higher risk of CHD Background

PD also induces production of proinflammatory cytokines and acute- phase proteins. A positive association between CRP, fibrinogen levels, and peripheral leukocyte count with periodontitis has been documented by various studies Background

 This link of PD and Systemic Inflammatory markers is further strengthened by intervention studies where PT has shown reduction in inflammatory markers associated with CHD risk Background

Investigate the effect of conventional, mechanical, non-surgical periodontal treatment on serum levels of hsCRP, fibrinogen and white blood cells in CHD patients with periodontitis. Aim of study

 Observe changes in clinical periodontal parameters of BOP, PPD, and CAL and Serum levels of hsCRP, Fibrinogen and WBCs following Periodontal therapy  Compare these changes to corresponding levels in periodontally untreated CHD patients  Determine the effect of PT on the reduction of CHD risk marker Objectives of study

Study Design A single-blind, parallel-arm, Randomized Controlled Intervention Trial Subjects Angiographically confirmed CHD patients with moderate to severe periodontitis

CHD was defined as having  >50% stenosis of ≥1 coronary artery Oral /Periodontal Status was defined as  ≥ 14 periodontally evaluable natural teeth  > 20% of sites BOP+  ≥ 4 teeth with ≥ 1 site with PPD ≥ 4 mm and CAL ≥ 3 mm at same site

Exclusion Criteria Diseases or conditions affecting or potentially confounding Periodontal status or systemic Inflammatory Biomarker levels

Sample Size  Based on primary endpoint (serum CRP), Sample Size was calculated for 317 CHD patients with periodontitis to be randomized into intervention and control group at 2:1 ratio with 90% power to detect significant difference between groups.

Based on the observations of our pilot study 1. Reduction in BOP sites to ≤20% 2. Reduction in Sites with PPD ≥ 4 mm by 50% 3. Reduction in Serum inflammatory marker levels by 20% Level of Achievement after Periodontal Treatment

All CHD Subjects were on cardiac medications that included Antiplatelets, betablockers, ARBs, ACE inhibitors, calcium channel antagonists, statins, diuretics and nitrates. Subjects were monitored for change in status of medications during follow-up visits Cardiac medications

RESULTS Based on 317 recruited subjects ITT Analysis was carried out A comparison of Intervention and Control groups at baseline revealed NO Significant Differences with respect to Demographic and Medical parameters Periodontal and systemic Inflammatory variables

Changes in Periodontal Parameters E1, E2, E3 indicate 1 st, 2 nd, and 3 rd Examination stages

E1 and E3 indicate 1 st and 3 rd Examination Stages Changes in Periodontal Parameters

E1 and E3 indicate 1 st and 3 rd Examination Stages Changes in Periodontal Parameters

E1, E2 and E3 indicate 1 st, 2 nd and 3 rd Examination Stages Changes in Inflammatory Parameters

E1, E2 and E3 indicate 1 st, 2 nd and 3 rd Examination Stages Changes in Inflammatory Parameters

E1, E2 and E3 indicate 1 st, 2 nd and 3 rd Examination Stages Changes in Inflammatory Parameters

Effect of Periodontal Therapy on CRP ( > 3mg/L) based CHD Risk Category ARR = 48.5%-36% = 12.5% (χ 2 =4.381, p=0.036) Relative Risk Ratio = 1.34 Relative Risk Reduction= 26% Periodontal therapy may reduce high-risk CRP levels by 26% in CHD patients NNT = 1 out of 8 CHD Patients with Moderate-Severe periodontitis may benefit from PT and lower serum CRP levels to mild risk (

Conclusion Treatment of periodontitis by conventional non-surgical periodontal therapy in CHD patients contributes to significant reduction in serum levels of systemic inflammatory markers associated with CHD Risk

This reduction in systemic markers of CHD risk might lead to CHD risk reduction. Periodontal screening of CHD patients might help identify individuals who may benefit from periodontal therapy. Conclusion

 Evidence suggests an association of PD and CHD and CHD risk markers of CRP, Fibrinogen and WBCs are raised in patients with Periodontitis. Treatment studies provide conflicting results regarding the systemic effects of mechanical periodontal therapy. This trial lends further evidence to such researches. Clinical Relevance/ Rationale of Study

 In the absence of any change in systemic medication, mechanical periodontal therapy significantly reduces serum levels of C- reactive protein, fibrinogen and white blood cells in CHD patients Principal Findings

 Treatment of CHD patients with periodontitis using mechanical periodontal therapy can result in significant reduction of CHD risk markers Practical Implications